Last viewed: NGM


Prices are updated after-hours



nasdaq:NGM NGM Biopharmaceuticals, Inc.

NGM 4 | $12.92 -12.23% 0.0% | twitter stocktwits trandingview |
Health Technology

(0.0% 1d) (-6.6% 1m) (-34.5% 1y) (0.0% 2d) (-12.2% 3d) (-8.4% 7d) (258.4% volume)
Earnings Calendar:
http://www.ngmbio.com
Sec Filling | Patents | 186 employees

(US) NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Its portfolio include aldafermin (NGM282), NGM313, NGM120, NGM217, NGM621, and NGM395. The company was founded by Jin-Long Chen in 2008 and is headquartered in South San Francisco, CA.

liver   metabolic  

add to watch list email alert is off

Price chart


% (High / Open) change chart




Press-releases


NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors
Published: 2022-05-12 (Crawled : 14:00) - biospace.com/
NGM 4 | $12.92 -12.23% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 0.95% H: 12.73% C: 6.74%

ngm438 treatment for
NGM Bio to Participate in Upcoming Investor Conferences
Published: 2022-04-20 (Crawled : 21:00) - globenewswire.com
NGM 4 | $12.92 -12.23% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 0.58% H: 1.02% C: -5.27%


NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors
Published: 2022-03-31 (Crawled : 22:00) - biospace.com/
NGM 4 | $12.92 -12.23% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 0.51% H: 0.64% C: -2.62%

ngm831 treatment trial
NGM Bio to Host the First of Four Virtual R&D Events on March 30, 2022
Published: 2022-03-21 (Crawled : 14:00) - biospace.com/
NGM 4 | $12.92 -12.23% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: -1.12% H: 2.37% C: -4.04%


NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-03-01 (Crawled : 23:00) - globenewswire.com
NGM 4 | $12.92 -12.23% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: -0.35% H: 13.31% C: 12.2%

financial results report results
NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Published: 2022-02-07 (Crawled : 14:00) - biospace.com/
NGM 4 | $12.92 -12.23% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 3.61% H: 6.52% C: 6.0%

ngm621 fast track designation treatment fda fast track macular designation
NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 Trial of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination with Merck’s KEYTRUDA® (pembrolizumab)
Published: 2021-12-06 (Crawled : 15:30) - biospace.com/
NGM 4 | $12.92 -12.23% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: -0.33% H: 0.0% C: 0.0%

ongoing trial phase 1 keytruda collaboration antibody
NGM Bio to Participate in Upcoming Investor Conferences
Published: 2021-11-09 (Crawled : 21:00) - biospace.com/
NGM 4 | $12.92 -12.23% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 0.82% H: 0.48% C: 0.29%

conference
NGM Bio Provides Business Highlights and Reports Third Quarter 2021 Financial Results
Published: 2021-11-04 (Crawled : 23:00) - biospace.com/
NGM 4 | $12.92 -12.23% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 0.8% H: 0.2% C: -0.1%

financial results results
NGM Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose Escalation Study of NGM120 in Patients with Advanced Solid Tumors at the ESMO Virtual Congress 2021
Published: 2021-09-16 (Crawled : 14:00) - biospace.com/
NGM 4 | $12.92 -12.23% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: -2.5% H: 1.16% C: -4.64%

solid tumors ongoing phase 1 phase 1b
See all


Last 15 days Sec forms
File Id Form Published Date Transaction Date Direction Code Amount Transacted Owned Amount
0000899243-22-022214 4 2022-06-13 2022-06-09 Buy P 32477 90442
0000899243-22-022214 4 2022-06-13 2022-06-09 Buy P 951684 2650177
0000899243-22-022212 4 2022-06-13 2022-06-09 Buy P 32477 90442
0000899243-22-022212 4 2022-06-13 2022-06-09 Buy P 951684 2650177
0000899243-22-022210 4 2022-06-13 2022-06-09 Buy P 32477 90442
0000899243-22-022210 4 2022-06-13 2022-06-09 Buy P 951684 2650177
0000899243-22-021216 4 2022-06-06 2022-06-02 Buy P 1129 57965
0000899243-22-021216 4 2022-06-06 2022-06-02 Buy P 33071 1698493
0000899243-22-020690 4 2022-06-02 2022-06-01 Buy P 3036 56836
0000899243-22-020690 4 2022-06-02 2022-06-01 Buy P 88964 1665422
0000899243-22-020690 4 2022-06-02 2022-05-31 Buy P 2040 53800
0000899243-22-020690 4 2022-06-02 2022-05-31 Buy P 59766 1576458


Your Today's Watch List
Sign in to create a watchlist
Last 48 Hours Insiders Buying
ALTG P 3227 | $9.29 -2.52% 0.0% | twitter stocktwits trandingview |
Distribution Services
| 01:40
SKIL P 30000 | $3.61 -6.96% 2.22% | twitter stocktwits trandingview |
Information
| 23:50
CAMP P 20000 | $4.65 -1.27% 0.86% | twitter stocktwits trandingview |
Electronic Technology
| 16:00